| First Author | Young C | Year | 2022 |
| Journal | Biol Open | Volume | 11 |
| Issue | 6 | PubMed ID | 35603697 |
| Mgi Jnum | J:326032 | Mgi Id | MGI:7293393 |
| Doi | 10.1242/bio.059143 | Citation | Young C, et al. (2022) Intrinsic function of the peptidylarginine deiminase PADI4 is dispensable for normal haematopoiesis. Biol Open 11(6):bio059143 |
| abstractText | Peptidylarginine deiminases (PADIs) are strongly associated with the development of autoimmunity, neurodegeneration and cancer but their physiological roles are ill-defined. The nuclear deiminase PADI4 regulates pluripotency in the mammalian pre-implantation embryo but its function in tissue development is unknown. PADI4 is primarily expressed in the bone marrow, as part of a self-renewal-associated gene signature. It has been shown to regulate the proliferation of multipotent haematopoietic progenitors and proposed to impact on the differentiation of haematopoietic stem cells (HSCs), suggesting that it controls haematopoietic development or regeneration. Using conditional in vivo models of steady state and acute Padi4 ablation, we examined the role of PADI4 in the development and function of the haematopoietic system. We found that PADI4 loss does not significantly affect HSC self-renewal or differentiation potential upon injury or serial transplantation, nor does it lead to HSC exhaustion or premature ageing. Thus PADI4 is dispensable for cell-autonomous HSC maintenance, differentiation and haematopoietic regeneration. This work represents the first study of PADI4 in tissue development and indicates that pharmacological PADI4 inhibition may be tolerated without adverse effects. |
